Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data th...

Descripción completa

Detalles Bibliográficos
Autores: García Quintanilla, Laura, Luaces Rodríguez, Andrea, Gil Martinez, Maria, MONDELO GARCIA, CRISTINA, Maroñas, O., Mangas-Sanjuan, V., González Barcia, Miguel, ZARRA FERRO, IRENE, Aguiar Fernández, Pablo, Otero-Espinar, F. J., Fernández Ferreiro, Anxo
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/15465
Acceso en línea:https://www.ncbi.nlm.nih.gov/pubmed/31370346
http://hdl.handle.net/20.500.11940/15465
Access Level:acceso abierto
Palabra clave:FPGMX
CHUS
IDIS
id ES_53c96cdc07f4d8daf83c903f16b2fc88
oai_identifier_str oai:runa.sergas.gal:20.500.11940/15465
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular DegenerationGarcía Quintanilla, LauraLuaces Rodríguez, AndreaGil Martinez, MariaMONDELO GARCIA, CRISTINAMaroñas, O.Mangas-Sanjuan, V.González Barcia, MiguelZARRA FERRO, IRENEAguiar Fernández, PabloOtero-Espinar, F. J.Fernández Ferreiro, AnxoFPGMXCHUSIDISIntravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an important role in vitreous distribution and elimination. The pharmacokinetic parameters that were collected differ depending on the species that were involved in the studies and on physiological and pathological conditions, such as vitrectomy and lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used in clinical practice is of vital importance.2019info:eu-repo/semantics/articlehttps://www.ncbi.nlm.nih.gov/pubmed/31370346http://hdl.handle.net/20.500.11940/15465reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/154652026-06-12T08:40:47Z
dc.title.none.fl_str_mv Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
title Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
spellingShingle Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
García Quintanilla, Laura
FPGMX
CHUS
IDIS
title_short Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
title_full Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
title_fullStr Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
title_full_unstemmed Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
title_sort Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
dc.creator.none.fl_str_mv García Quintanilla, Laura
Luaces Rodríguez, Andrea
Gil Martinez, Maria
MONDELO GARCIA, CRISTINA
Maroñas, O.
Mangas-Sanjuan, V.
González Barcia, Miguel
ZARRA FERRO, IRENE
Aguiar Fernández, Pablo
Otero-Espinar, F. J.
Fernández Ferreiro, Anxo
author García Quintanilla, Laura
author_facet García Quintanilla, Laura
Luaces Rodríguez, Andrea
Gil Martinez, Maria
MONDELO GARCIA, CRISTINA
Maroñas, O.
Mangas-Sanjuan, V.
González Barcia, Miguel
ZARRA FERRO, IRENE
Aguiar Fernández, Pablo
Otero-Espinar, F. J.
Fernández Ferreiro, Anxo
author_role author
author2 Luaces Rodríguez, Andrea
Gil Martinez, Maria
MONDELO GARCIA, CRISTINA
Maroñas, O.
Mangas-Sanjuan, V.
González Barcia, Miguel
ZARRA FERRO, IRENE
Aguiar Fernández, Pablo
Otero-Espinar, F. J.
Fernández Ferreiro, Anxo
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv FPGMX
CHUS
IDIS
topic FPGMX
CHUS
IDIS
description Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an important role in vitreous distribution and elimination. The pharmacokinetic parameters that were collected differ depending on the species that were involved in the studies and on physiological and pathological conditions, such as vitrectomy and lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used in clinical practice is of vital importance.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://www.ncbi.nlm.nih.gov/pubmed/31370346
http://hdl.handle.net/20.500.11940/15465
url https://www.ncbi.nlm.nih.gov/pubmed/31370346
http://hdl.handle.net/20.500.11940/15465
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408140543393792
score 15.301603

Similares en LA Referencia